Description
Pharmacological action
Antifibrin.
Inhibits the action of the plasmin activator and plasminogen, has a hemostatic effect in bleeding associated with increased fibrinolysis, as well as anti-allergic and anti-inflammatory effects by inhibiting the formation of kinins and other active peptides involved in allergic and inflammatory reactions.
Indications
Treatment and prevention of bleeding due to increased total fibrinolysis (malignant neoplasms of the pancreas, prostate gland surgery, postpartum hemorrhage, manual separation of the sequelae of liver disease leukemia complications of streptokinase therapy) and local fibrinolysis (uterine, nasal, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, cervical conization for carcinoma, tooth extraction in patients with hemorrhagic diathesis).
Hereditary angioedema, allergic diseases (eczema, allergic dermatitis, urticaria, drug and toxic rash).
Inflammatory diseases of the oral cavity (stomatitis, aphthae of the mucous membrane), pharynx (tonsillitis, pharyngitis, laryngitis).
Contraindications
Hypersensitivity Hypersensitivity to tranexamic acid. to tranexamic acid.
Recommended use
Individual, depending on the clinical situation.
A single dose for oral administration is 1-1.5 g, the frequency of administration is 2-4 times / day, the duration of treatment is 3-15 days.
A single dose for iv administration is 10-15 mg / kg.
If re-use is necessary, the interval between each administration should be 6-8 hours.
In case of violation of the excretory function of the kidneys, a correction of the dosage regimen is necessary: at a level of serum creatinine in the blood of 120-250 μmol / l, it is prescribed orally at 15 mg / kg, iv – 10 mg / kg 2 times / day with a level of serum creatinine of 250-500 μmol / l – inside and iv the same single dose, multiplicity – 1 time / day with a serum creatinine level of more than 500 μmol / l – inside 7.5 mg / kg, iv 5 mg / kg, multiplicity – 1 time / day.
Special instructions
Caution should be used in combination with heparin and anticoagulants in patients with coagulation disorders and thrombosis (cerebral vascular thrombosis, myocardial infarction, thrombophlebitis) or the threat of their development.
Before and during treatment, consultations with an ophthalmologist are necessary (determination of visual acuity, color vision, fundus condition).
Composition
Film-coated tablets of white or almost white color, round, biconvex in a section of white or almost white color
1 tablet
tranexamic acid 250 mg
Excipients:
microcrystalline cellulose – 45.05 mg,
pregelatinized starch – 4.85 mg,
carboxymethyl starch sodium – 6.2 mg,
talcum – 7.99 mg,
silicon dioxide colloidal – 6.01 mg,
sodium stearyl. 9 mg.
Shell:
VIVACOAT® RA-1P-000 [hypromellose 6 cPs (hydroxypropyl methylcellulose 6cPc) – 3.51 mg, titanium dioxide – 2.7 mg, polydextrose (E1200) – 1.35 mg, talc – 0.9 mg, polyethylene glycol-3350 – 0.54] 9 mg
Side effects
From the digestive system: loss of appetite, nausea, diarrhea, heartburn.
From the side of the central nervous system: drowsiness, impaired color vision.
Allergic reactions: incl. skin rash, itching. From the digestive system: decreased appetite, nausea, diarrhea, heartburn.
From the side of the central nervous system: drowsiness, violation of color vision.
Allergic reactions: incl. skin rash, itching.
Active ingredient
Tranek self acid
Dispensing conditions from
pharmacies Prescription
Formulation
tablets
